Improvement in Social Competence With Short-Term Atypical Antipsychotic Treatment: A Randomized, Double-Blind Comparison of Quetiapine Versus Risperidone for Social Competence, Social Cognition, and Neuropsychological Functioning
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: While neuropsychological test performance is correlated with social outcomes in patients with schizophrenia, there is little evidence to date that changes in neuropsychological performance are associated with changes in these outcomes. As part of an efficacy and tolerability study of atypical antipsychotics, the authors used a performance-based measure of social competence as a short-term outcome measure and examined the correlations between changes in social competence and improvements on neuropsychological tests. METHOD: Patients with schizophrenia were randomly assigned in a 1:1 ratio to receive treatment with either quetiapine (dose range: 200-800 mg/day) or risperidone (dose range: 2-8 mg/day) for an 8-week period. RESULTS: Of 673 patients initially randomized, 289 had baseline and endpoint neuropsychological and functional competence data. Scores on the performance-based measure of social competence significantly improved with both treatments, as did a number of aspects of neuropsychological performance. Improvements in several aspects of neuropsychological performance were correlated with the extent of improvement in social competence. There were no overall differences between the treatments in their impact on social competence and neuropsychological performance. CONCLUSIONS: Short-term treatment with both quetiapine and risperidone resulted in improvements in social competence, with these improvements associated with improvements on some of the neuropsychological measures. In addition to their clinical importance, these results support the use of performance-based competence assessments as outcome measures in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS
Green, M. F., Kern, R. S., & Heaton, R. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.009 · Cited by 1,422
Cannon, M., Caspi, A., Moffitt, T. E., Harrington, H., Taylor, A., Murray, R. M., & Poulton, R. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.5.449 · Cited by 783
Buchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi020 · Cited by 438
Cornblatt, B. A., Lenzenweger, M. F., & Erlenmeyer-Kimling, L. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90188-1 · Cited by 399
Assessing Disability in Older Patients With Schizophrenia: Results From the WHODAS-II
McKibbin, C., Patterson, T. L., & Jeste, D. V. (2004) · Journal of Nervous & Mental Disease · doi:10.1097/01.nmd.0000130133.32276.83 · Cited by 149
Self-citationGuanfacine treatment of cognitive impairment in schizophrenia
Friedman, J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00249-4 · Cited by 113
Cited by
Green, M. F., Penn, D. L., Bentall, R., Carpenter, W. T., Gaebel, W., Gur, R. C., Kring, A. M., Park, S., Silverstein, S. M., & Heinssen, R. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm145 · Cited by 1,003
Facial Emotion Perception in Schizophrenia: A Meta-analytic Review
Kohler, C. G., Walker, J. B., Martin, E. A., Healey, K. M., & Moberg, P. J. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn192 · Cited by 930
Bowie, C. R., Leung, W. W., Reichenberg, A., McClure, M. M., Patterson, T. L., Heaton, R. K., & Harvey, P. D. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.022 · Cited by 583
Self-citationSocial cognition in schizophrenia: an overview
Penn, D. L., Sanna, L. J., & Roberts, D. L. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn014 · Cited by 574
Prosocial effects of oxytocin and clinical evidence for its therapeutic potential
Striepens, N., Kendrick, K. M., Maier, W., & Hurlemann, R. (2011) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2011.07.001 · Cited by 283
“Pharmacological treatments, which block dopamine D2 receptors, are effective for delusions and hallucinations but less so for disabling cognitive and motivational impairments [79,179].”
Background
Metadata
- Authors
- Harvey, P. D., Patterson, T. L., Potter, L. S., Zhong, K., & Brecher, M.
- Venue
- American Journal of Psychiatry
- Published
- 2006-11
- Volume
- 163
- Issue
- 11
- Pages
- 1918-1925
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2112167247
- Cited by
- 147
- References
- 8
- FWCI
- 9.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improvement in Social Competence With Short-Term Atypical Antipsychotic Treatment: A Randomized, Double-Blind Comparison of Quetiapine Versus Risperidone for Social Competence, Social Cognition, and Neuropsychological Functioning. https://app.cochat.ai/papers/10.1176/ajp.2006.163.11.1918
- The paper
- Harvey, P. D., Patterson, T. L., Potter, L. S., Zhong, K., & Brecher, M. (2006). Improvement in Social Competence With Short-Term Atypical Antipsychotic Treatment: A Randomized, Double-Blind Comparison of Quetiapine Versus Risperidone for Social Competence, Social Cognition, and Neuropsychological Functioning. American Journal of Psychiatry. https://doi.org/10.1176/ajp.2006.163.11.1918
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.